Overview

Study of Ianalumab Versus Placebo in Addition to First-line Corticosteroids in Primary Immune Thrombocytopenia (ITP)

Status:
Not yet recruiting
Trial end date:
2028-03-14
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the effect of two different doses of ianalumab versus placebo in addition to first-line corticosteroids in maintaining platelet count ≥30 G/L in adult participants with primary ITP.
Phase:
Phase 3
Details
Lead Sponsor:
Novartis Pharmaceuticals